These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1407 related articles for article (PubMed ID: 31020659)

  • 1. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
    Edvinsson L; Haanes KA; Warfvinge K; Krause DN
    Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine.
    Jinesh S
    Inflammopharmacology; 2023 Oct; 31(5):2245-2251. PubMed ID: 37421480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment.
    Kuzawińska O; Lis K; Cessak G; Mirowska-Guzel D; Bałkowiec-Iskra E
    Neurol Neurochir Pol; 2016; 50(6):463-467. PubMed ID: 27553188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine.
    Durham PL; Vause CV
    CNS Drugs; 2010 Jul; 24(7):539-48. PubMed ID: 20433208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment.
    Tfelt-Hansen PC
    J Headache Pain; 2009 Dec; 10(6):389-91. PubMed ID: 19779958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
    Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment.
    Edvinsson L; Warfvinge K
    Cephalalgia; 2019 Mar; 39(3):366-373. PubMed ID: 29020807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.
    Villalón CM; Olesen J
    Pharmacol Ther; 2009 Dec; 124(3):309-23. PubMed ID: 19796656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CGRP receptors in the control of pain and inflammation.
    Benemei S; Nicoletti P; Capone JG; Geppetti P
    Curr Opin Pharmacol; 2009 Feb; 9(1):9-14. PubMed ID: 19157980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigens and Antibodies in Disease With Specifics About CGRP Immunology.
    Taylor FR
    Headache; 2018 Nov; 58 Suppl 3():230-237. PubMed ID: 30187471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
    Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
    Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K; Michael RL; Rapoport AM
    Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CGRP Pathway in Migraine as a Viable Target for Therapies.
    Edvinsson L
    Headache; 2018 May; 58 Suppl 1():33-47. PubMed ID: 29697153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting calcitonin gene-related peptide: a new era in migraine therapy.
    Charles A; Pozo-Rosich P
    Lancet; 2019 Nov; 394(10210):1765-1774. PubMed ID: 31668411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.